. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Pediatr Clin North Am. 2015 Feb;62(1):139–165. doi: 10.1016/j.pcl.2014.09.010

Table 7.

Results of recent trials for pediatric intermediate and high-risk Hodgkin lymphoma

Group	Study	N	Definition	Chemotherapy	RT (Dose, Field)	EFS or DFS, OS (y)
Europe
German Society of Pediatric Oncology and Hematology	GPOH-HD-95¹¹⁹	341	Intermediate: I_EA/B; II_EA; IIB; IIIA High: II_EB; III_EA/B; IIIB; IV	2 OPPA/OEPA + 4 COPP.	CR after cycle 2: no RT PR after cycle 2: 20–35 Gy IF	84.5%, 93.2% (10 y)
German Society of Pediatric Oncology and Hematology	GPOH-HD-2002⁶⁰	Intermediate: 139 High: 239	Intermediate: I_EA/B; II_EA; IIB; IIIA High: II_EB; III_EA/B; IIIB; IV	OPPA (F); OEPA (M) × 2 Intermediate: COPDAC × 2 High: COPDAC × 4	19.8–35 Gy IF	Intermediate: 88.3%, 99.5% High: 86.9%, 94.9% (5 y)

North America
CCG, POG, and COG	CCG 5942⁵⁹	Intermediate: 394 High: 141	Intermediate: IA, IB, IIA with adverse features^a; IIB, III High: IV	Intermediate: COPP/ABV × 6 High: COPP/ABV, CHOP, Etoposide/Cytarabine × 2	CR after cycle 6: randomized to 21 Gy IFRT vs no RT PR: 21 Gy IF	Intermediate: RT: 87%, 95% No RT: 83%, 100% High: RT: 90%, 100% No RT: 81%, 94% (EFS P<.05)
	P9425¹²²	Intermediate: 53 High: 163	Intermediate: IB, IIA_LMA, IIIA High: IIB, IIIB, IV	DBVE-PC × 3–5 (based on response after cycle 3)	25.5 Gy IF	Intermediate: 84%, OS NR High: 85%, OS NR (5 y)
	C59704¹²³	99	IIB/IIIB + bulk, IV	BEACOPP × 4 M RER: ABVD × 2 F RER: COPP/ABV × 4 SER: BEACOPP × 4	M RER: 21 Gy IF F RER: No RT SER: 21 Gy IF	94%, 97% (5 y)
	AHOD0031⁴⁶	1712	IA, IIA + bulk, IB, IIB, IIIA, IVA	ABVE-PC × 4 SER: randomized DECA × 2	Randomized RER after cycle 2 and CR after cycle 4: no RT All others: 21 Gy IF	85.6%, 98.2% (3 y)

Abbreviations: ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; COPDac, cyclophosphamide, vincristine, prednisone, dacarbazine; COPP/ABV, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine; CR, complete response; DBVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; DECA, dexamethasone, etoposide, cisplatin, cytarabine; F, female; IF, involved field; M, male; OEPA, vincristine, etoposide, prednisone, doxorubicin; OPPA, vincristine, procarbazine, prednisone, doxorubicin; PR, partial response; RER, rapid early responder; RT, radiation therapy; SER, slow early responder.

Adverse features = hilar disease, bulk, ≥4 nodal regions, mediastinal tumor.